Oruka's 61% Skin-Clearance Result Moves ORKA Toward Phase 3

Oruka Therapeutics has cleared an important efficacy hurdle for ORKA-001, but the result still needs to survive longer follow-up and a much larger Phase 3 program. In the 187-patient Phase 2b EVERLAST-B trial, 61% of patients who received the highest 600 mg dose achieved PASI 100, meaning complete skin clearance, at week 16. No placebo patients reached that mark. The same high-dose group posted an 86% PASI 90 response, which means at least a 90% improvement in psoriasis severity.

Those figures are unusually strong for a mid-stage psoriasis study, and they explain why Guggenheim reiterated a Buy rating and a $200 price target. The firm estimates that ORKA-001 could eventually generate about $7 billion in peak global sales. That number is an analyst forecast, not company guidance, and it depends on regulatory approval, competitive positioning and commercial adoption that remain years away.

The trial also provides useful safety context. Treatment-emergent adverse events were reported in 39% of patients receiving the 600 mg dose, compared with 43% in the placebo group. Upper respiratory tract infection and headache were among the common events. Oruka said the study will continue through week 100, so the next question is whether deep responses last without revealing new safety concerns. Longer-term data are expected in December, followed by a planned Phase 3 start in the first half of 2027.

The comparison with AbbVie's Skyrizi is central to the investment case. Guggenheim said the ORKA-001 data showed a 15 to 20 percentage-point advantage in PASI 100 versus Skyrizi results. Cross-trial comparisons can be informative, but they are not equivalent to a head-to-head study because patient populations, trial designs and timing may differ. ORKA-001's proposed infrequent dosing could also matter commercially, yet that benefit must be demonstrated alongside durable efficacy.

Oruka has financial room to advance the program. It reported $1.124 billion of cash, cash equivalents and marketable securities at June 30, followed by about $122.5 million of net proceeds from a July at-the-market offering. Management says existing funds should support ORKA-001 through an anticipated biologics license application and continue development of ORKA-002. The company remains clinical-stage, however, with no product revenue. Its six-month net loss was $73.0 million and operating cash use was $56.7 million.

The week-16 result makes ORKA-001 a credible late-stage contender rather than a proven product. The December durability update and the Phase 3 design will determine whether the early efficacy advantage can support the valuation expectations now attached to the stock.